Neurotrophin (NT) receptors are coupled to numerous signaling networks that play critical roles in neuronal survival and plasticity. Several non-peptide small molecule ligands have recently been reported that bind to and activate specific tropomyosin-receptor kinase (Trk) NT receptors, stimulate their downstream signaling, and cause biologic effects similar to, though not completely overlapping, those of the native NT ligands. Here, in silico screening, coupled with low-throughput neuronal survival screening, identified a compound, LM22B-10, that, unlike prior small molecule Trk ligands, binds to and activates TrkB as well as TrkC. LM22B-10 increased cell survival and strongly accelerated neurite outgrowth, superseding the effects of brain-derived neurotrophic factor (BDNF), NT-3 or the two combined. Additionally, unlike the NTs, LM22B-10 supported substantial early neurite outgrowth in the presence of inhibiting glycoproteins. Examination of the mechanisms of these actions suggested contributions of the activation of both Trks and differential interactions with p75 NTR , as well as a requirement for involvement of the Trk extracellular domain. In aged mice, LM22B-10 activated hippocampal and striatal TrkB and TrkC, and their downstream signaling, and increased hippocampal dendritic spine density. Thus, LM22B-10 may constitute a new tool for the study of TrkB and TrkC signaling and their interactions with p75
Introduction
Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3) are members of the neurotrophin (NT) protein family that act through their cognate tropomyosin-receptor kinase (Trk) receptors (NGF/TrkA, BDNF/ TrkB, NT-3/TrkC) and the common NT receptor p75 (p75 NTR ). NT signaling via Trks strongly influences neuronal survival, differentiation and synaptic function via phospholipase Cg1 (PLCg), mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase pathways (PI3K) (Chao, 2003; Huang and Reichardt, 2003; Kaplan and Miller, 2000; Longo and Massa, 2013) . Numerous neurologic diseases and conditions exhibit constituent alterations in expression and/or function of NTs or their receptors, and show mitigation of pathology and/or symptoms in model systems treated with agents that modulate NT receptor activity (see for review). Moreover, several groups have identified small molecules that interact with Trks or p75 NTR and induce downstream signaling and biologic effects, including, TrkA activators: compound D3 (Maliartchouk et al., 2000) , gambogic amideet al., 2006) and THX-B (Bai et al., 2010) . In addition, peptidomimetic TrkC ligands have been reported, some of which differentially promote neurite outgrowth and survival (Chen et al., 2009; Zaccaro et al., 2005) . The mechanisms and applications of these compounds and their derivatives remain areas of active investigation. We previously identified selective TrkB ligands (Massa et al., 2010 ) that bind to the extracellular domain of TrkB, promote neuronal survival, and activate AKT and ERK pathways in a TrkBdependent fashion. One of these, LM22A-4, has been shown to promote motor recovery after ischemic stroke (Han et al., 2012) and traumatic brain injury (Massa et al., 2010) , and to rescue TrkB phosphorylation deficits, improve respiratory function and acutely reverse spontaneous apnea and other respiratory abnormalities in a mouse model of Rett syndrome (Schmid et al., 2012; Kron et al., 2014) . In addition, LM22A-4 reduced TrkB signaling deficits, motor impairment, and neuropathology in two Huntington's Disease mouse models (Simmons et al., 2013) , promoted TrkB activation and differentiation in cementoblasts in vitro (Kajiya et al., 2014) , and stimulated TrkB activation in intestinal smooth muscle cells and enhanced cholinergic-induced intestinal contraction (AlQudah et al., 2014) . In the present study, in silico screening with a pharmacophore based on the BDNF loop II domain, coupled with low-throughput in vitro neurotrophic assays, unexpectedly yielded a small molecule with binding selectivity for both TrkB and TrkC and signaling and biological effects distinct from those stimulated by BDNF or NT-3.
Material and methods

Materials
LY294002, K252a, PD98059, PP2 and U73132 were purchased from Calbiochem (La Jolla, CA); adenosine and pituitary adenylate cyclase-activating polypeptide 27 (PACAP27) were purchased from Sigma (St. Louis, MO); and recombinant BDNF and NT-3 from PeproTech (Rocky Hill, NJ). -amino]-phenyl]-(4-chloro-phenyl)-methyl]-phenyl]-(2-hydroxy-ethyl)-amino]-ethanol) was custom manufactured by Ricerca Biosciences LLC (Concord, OH). Each preparation was characterized by high-performance liquid chromatography (HPLC), nuclear magnetic resonance spectrometry and liquid chromatography/mass spectrometry (LC-MS) and had a purity of greater than 97.8%. The molecular weight and formula of the compound were further confirmed in our laboratory by high-resolution MS. For use in vitro, LM22B-10 was dissolved in 0.04 N HCl prior to dilution (1:10,000) in culture medium. For in vivo intraperitoneal (IP) administration, LM22B-10 in 0.04 N HCl was mixed with Cremophor (Sigma) and 2X phosphate buffered saline (2X PBS; Sigma). This solution was adjusted to pH 5 to yield 1X PBS (0.01 M sodium phosphate; 0.138 M NaCl; 0.0027 M KCl) containing 0.02 N HCl and 2.5% Cremophor. Mouse monoclonal anti-phospho-ERK T202/Y204 , rabbit polyclonal anti-ERK42/44, mouse monoclonal anti-phospho-AKT
S473
, rabbit polyclonal anti-AKT, rabbit polyclonal anti-TrkC, rabbit monoclonal anti-p75 NTR , rabbit polyclonal anti-Shc, sitespecific rabbit polyclonal anti-Trk Y490 and site-specific rabbit polyclonal anti-Trk Y674/675 were obtained from Cell Signaling 
Construction of chimeric TrkA-TrkB receptors
Rat full-length wild-type (WT) TrkB, and TrkA/B-1.4B and À4.1B chimeric expression vectors were custom made at Vigene Biosciences, Inc. (Rockville, MD), as described previously (Perez et al., 1995; Zaccaro et al., 2001) . TrkA/B-1.4B contains the entire rat TrkA extracellular domain fused to the rat TrkB intracellular domain. In TrkA/B-4.1B constructs, the TrkB IgG-C2 domain is replaced with the TrkA IgG-C2 domain, and the resulting sequence contains cysteine clusters 1 and 2 (Cys 1, 2), a leucine motif (LRM), and the IgG-C1 domain of TrkB, the IgG-C2 domain of TrkA, and the intracellular domain of TrkB. All chimeric constructs were confirmed by sequencing and were cloned into the pENTER expression vector that contains a CMV promoter and selection gene providing resistance to kanamycin (Vigene Biosciences, Inc.).
Primary neuronal cultures and cell survival assays
Hippocampal neuron cultures were prepared from embryonic day 16 (E16) CF1 mouse fetuses, as described previously (Walter et al., 2011; Yang et al., 2006) . Under the low density conditions used here, neuronal survival is dependent, in part, on addition of exogenous NTs (Lindholm et al., 1996; Walter et al., 2011) . LM22B-10 was dissolved in water containing 0.04 N HCl and diluted in culture medium to a final dilution of 1:10,000 HCl. For controls, HCl was diluted in culture media in equivalent amounts. Cell survival following a 48 h exposure to BDNF or LM22B-10 was measured by morphological criteria using staining for b-tubulin III antibody which allows visualization of neurites and cell bodies Walter et al., 2011) , quantification of ATP levels using the ViaLight assay (Lonza Group Ltd., Rockland, ME), or by terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL) with DAPI staining (Walter et al., 2011; Yang et al., 2006 Yang et al., , 2008 . Dose-response curves were generated with SigmaPlot (Systat Software Inc., San Jose, CA).
Neurite outgrowth assay
Mouse E16 dissociated hippocampal neurons were seeded on poly-L-lysine-coated coverslips in 12 well plates at a density of 4 Â 10 4 cells/well. Neurons were treated with control medium, BDNF, NT-3 and/or LM22B-10 or co-treated with MAG-Fc at 25 mg/ ml or CSPG at 1 mg/ml. For the MAG and CSPG assays, culture medium contained 0.1% fetal bovine serum (FBS). For 7, 14 and 21 day in vitro neurite assays, culture medium was changed to Neurobasal/ B27 at day 3 with treatments continuing in this new medium. Culture medium was changed every three days with the addition of fresh NTs and compound. Cultures were maintained for either 24 h (for the MAG and CSPG assay) or 48 h (for antibody inhibition experiments and others), or other time points, then fixed with 4% paraformaldehyde (PFA), and stained with anti-b-tubulin III antibody. Neurite length was measured using Neurolucida software (v.10, MBF Biosciences). Random images, 5e10 for each condition, from 3 independent experiments were measured. For survival and neurite outgrowth inhibitor studies standard concentrations from published works were used, with final concentrations of: 200 nM K252a, 10 mM LY294002, 50 mM PD98059, 10 mM PP2 and 1 mM U73132, in addition to 0.7 nM BDNF, 0.7 nM NT-3 and/or 1000 nM LM22B-10. For antibody inhibition studies, TrkB, TrkC, or p75 NTR (rat monoclonal or rabbit polyclonal) antibodies and control nonimmune serum were used at final dilutions of 1:400 added concomitantly with BDNF, NT-3 and/or LM22B-10.
Transfection
For p75 NTR overexpression, control plasmid pDsRed (Clontech) or p75 NTR -RFP (Addgene, MA) was transfected into either 3T3-TrkB or 3T3-TrkC cells using Lipofectamine™ 3000 (Invitrogen), according to the manufacturer's instructions, as described previously . Cells were exposed to 0.7 nM BDNF, 0.7 nM NT-3 or 1000 nM LM22B-10 for 96 h, followed by the ViaLight survival assay, as described above. For p75 NTR siRNA expression in hippocampal neurons, control siRNA or p75 NTR siRNA (Santa Cruz) was transfected into mouse hippocampal neurons 2 h after cell seeding using Lipofectamine ® RNAiMAX (Invitrogen), according to the manufacturer's instructions. Cell survival following 48 h exposure to BDNF, NT-3 or LM22B-10 was measured by morphological criteria using staining for b-tubulin III antibody Walter et al., 2011) . For EGFP expression in hippocampal neurons, reporter plasmid (EGFP) was transfected into 14 DIV mouse hippocampal neurons using Lipofectamine 3000. After transfection, culture medium was changed to Neurobasal/B27 medium with or without the addition of BDNF or LM22B-10 for 24 h. Cells were then fixed and dendritic spine density measured using Neurolucida. For TrkA/B chimera transfection, human embryonic kidney 293 (HEK-293) cells were cultured in Dulbecco's modified Eagle Medium (DMEM) supplemented with 10% FBS (Invitrogen) on 60 mm culture dishes. After plating in a 12 well plate, cells were changed to serum free medium once 60e70% confluence was reached and then transiently transfected for 24 or 48 h using Lipofectamine 3000. In each condition, a total of 2 or 4 mg of plasmid DNA was used. After transfection the cells were treated with NGF (0.7 nM), BDNF (0.7 nM) or LM22B-10 (1000 nM) for 1 h and then harvested for Western blotting with anti-Trk Y674/675 or pan-Trk antibodies. NTR -expressing cells). Cells were seeded into 24-well plates (30,000 cells/well) and cultured in medium consisting of 50% PBS and 50% DMEM without supplements. Following exposure to growth factors (0.7 nM) or 1000 nM LM22B-10 for 72e96 h, cells were suspended in 50 ml lysis buffer, transferred to opaque 96-well culture plates and survival was measured using the ViaLight Assay.
Trk coupled bead-immobilization and LC-MS/MS LM22B-10 binding assay
To measure total LM22B-10 binding, each of the Fc-chimeric Trk family receptors and p75 NTR were bound on Protein A-decorated Dynabeads™ and incubated with increasing concentrations of LM22B-10. Beads (50 ml) were washed twice with binding buffer (10 mM EDTA, 0.1% BSA, PBS, pH 7.4) then incubated with each receptor at 1 mM in 50 ml of binding buffer for 1.5 h on an orbital shaker (Thermolyne AROS 160) at room temperature with mixing/ agitation every 30 min. After resuspension in 100 ml of binding buffer and spinning down to wash away unbound receptor, each vial was incubated on a shaker overnight at 4 C in 100 ml binding buffer containing LM22B-10 at concentrations of 0, 100, 250, 500, 750, 1000, 1500, or 2000 nM. Unbound LM22B-10 was washed away with 100 ml of binding buffer and the vials were incubated overnight at 37 C with trypsin in 20 mM ammonium acetate at a trypsin-receptor ratio of 1:20 (w/w). To measure non-specific binding, 50 ml of binding buffer was used instead of receptor solution. The samples were then stored in 4 C. For LC-MS/MS analysis, 180 ml of 10% acetonitrile in milliQ water was added to each vial, beads were mixed, the vials were centrifuged for 1 min at 3600 rpm at room temperature, and the supernatant transferred to polypropylene HPLC vials. Each sample (30 ml) was injected into either a Shimdadzu 20 series HPLC (Pleasanton, CA) or Agilent 1200 HPLC (Santa Clara, CA) with a Pinnacle DB biphenyl column, and identified using a Q-Trap 4000 (AB Sciex, Foster City, CA) spectrometer in MRM mode. The peak area was calculated using Analyst software. Fractional binding was computed as: (total boundnonspecifically bound compound)/saturation value. Total bound compound is the amount of compound released on trypsin treatment and nonspecifically bound compound is the amount released without trypsin treatment (in binding buffer). Saturation value is the maximum amount of compound bound to the beads measured on the day of analysis.
Cell-based binding assay
NIH-3T3 WT cells or NIH-3T3 cells expressing one of the four NT receptors were seeded into poly-L-lysine-coated 96-well plates (Fisher Scientific, Pittsburgh, PA). After reaching 85e95% confluence, Trk-expressing cells were incubated with their cognate NT and p75 NTR -expressing cells were incubated with BDNF, each at multiple concentrations with or without 1000 nM LM22B-10 for 45 min at 4 C with gentle shaking. After one wash with ice-cold PBS, cells were fixed with 4% PFA for 15 min, rinsed twice with PBS, and then incubated with anti-mouse monoclonal NGF antibody (1 mg/ml, Abcam, Cambridge, MA), anti-mouse monoclonal BDNF antibody (1 mg/ml, Sigma), or anti-rabbit polyclonal NT-3 antibody (1 mg/ml, Abcam) for 1 h at room temperature. Cells were then rinsed twice with PBS and incubated with DyLight 549-conjugated secondary antibody (1:500, Jackson ImmunoResearch Laboratory, Inc., West Grove, PA) for 1 h at room temperature followed by two washes. Fluorescent signals were measured at an excitation wavelength of 549 nm and emission of 568 nm using a Molecular Devices plate reader (Sunnyvale, CA). Duplicate wells were measured for each NT concentration. Background signal, determined from wells containing 3T3-cells lacking NT receptors incubated with a maximal level of NT, was subtracted. Data were normalized according to the maximum signal and were expressed as percentage of each NT maximum.
Cerep screen (radioligand binding assay)
To evaluate the specificity of LM22B-10, binding to a broad range of pharmacologically relevant receptors was assessed, 57 total, including numerous neurotransmitter and G-protein coupled receptors, using standard radioligand competition binding assays (ExpressSProfile) performed by Cerep Inc. (Seattle, WA). Experimental conditions are described on the Cerep website (www.cerep. fr).
Hippocampal synaptosome enriched fraction preparation
Hippocampal synaptosomes were collected using a previously published method (VanGuilder et al., 2010) , with some modifications. Briefly, hippocampal tissue was harvested from C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) at ages 15e17 months following one month of LM22B-10 treatment (50 mg/kg/day intraperitoneal (IP) and 5 mg/kg/day intranasal (IN)), rapidly exposed to ice-cold sucrose buffer (TEVP buffer: 10 mM Tris-HCl, pH 7.4, 320 mM sucrose, 4 mM HEPES, 1 mM Na 3 VO 4 , 1 mM EDTA) and sonicated for 10 s. Homogenates were incubated on ice for 30 min and then centrifuged to pellet the nuclear/cytoskeletal fraction (4 C, 1000 Â g, 12 min). The resulting supernatants were then centrifuged to pellet the synaptosomal fraction (4 C, 25,000 Â g, 30 min). Synaptosome samples were resuspended in a detergent-based protein lysis buffer (100 mM NaCl, 20 mM HEPES, 1 mM EDTA, 1 mM dithiothreitol, 1.0% Triton, 1 mM Na 3 VO 4 ) containing a Complete Mini EDTA-free Protease Inhibitor Cocktail Tablet (Roche Diagnostic GmbH, Mannheim, Germany) for every 10 ml lysis buffer and stored at À80 C.
Western blotting, immunoprecipitation, and kinase activity assays
For assays of Trk, AKT, ERK and PKC activation, 3T3-TrkA, 3T3-TrkB or 3T3-TrkC cells were seeded into 6 well plates and were grown in DMEM supplemented with 10% FBS to 50e60% confluence, then switched to serum free medium consisting of 50% PBS and 50% DMEM without supplements. Cells were exposed to NTs or LM22B-10 for 48 h and then culture medium was switched to 50% PBS/50% DMEM without NTs or LM22B-10 for 6 h. Next, cells were treated with serum-free DMEM containing the same NT or compound with which they had been previously cultured, 0.7 nM of one of the NTs or 1000 nM of LM22B-10 for 1 h. Cells were then harvested and used for Western blotting with phospho-specific antibodies then membranes were re-probed with antibodies detecting the total protein. All antibodies for immunoblotting were used at a dilution of 1:1000, with the following exceptions: pAKT, AKT, pERK, ERK were used at 1:2000; TrkB at 1:3000; PSD-95 and synaptophysin at 1:10,000. In some cases, 80e100 mg/ml of extracted protein was immunoprecipitated with TrkB antibody (1:100; Millipore 07e225). Half of the precipitated protein was retained for Westerns blots using the pY99 antibody (1:6000), which detects phosphorylated tyrosine residues; the other half was used for kinase activity assays using the Antibody Beacon Tyrosine Kinase Assay Kit (Invitrogen), according to manufacturer's instructions. Hippocampal neurons derived from E16 mice were cultured in poly-L-lysine coated 6 well plates (Corning Inc.; 5 Â 10 6 cells/well) in DMEM/F12
containing 10% FBS for 2 h, in Neurobasal/B27 medium for an additional 44 h, and then in serum-free DMEM/F12 for 2 h. Finally, NTs (0.7 nM), adenosine (100 mM), PACAP27 (100 nM), or LM22B-10 (1000 nM) with or without PP2 (10 mM) inhibitor were added for 1 h before cells were harvested and processed for western blot analysis, as described previously (Walter et al., 2011; Yang et al., 2003 
Immunofluorescent staining and quantification
Cultured hippocampal neurons were fixed in 4% PFA for 20 min, permeabilized for 6 min with 80% ice-cold methanol, and then incubated with the following primary antibodies: phospho-Trk specific antibodies (1:500), MAP2 antibody AP20 (1:1000), or btubulin III antibody (1:1000) in PBS. Secondary antibodies included donkey anti-rabbit and anti-mouse conjugated with either FTIC or Cy3 (1:400; Jackson ImmunoResearch Laboratories, Inc.). For quantitative analysis, experimenters were blind to the treatment conditions. Images were acquired with a 63Â objective on a Leica Confocal microscope. The total intensity of fluorescent pixels was measured using UN-Scan-it Gel & Graph Digitizing Software Ver. 6.14 (Silk Scientific, Inc.). Average pixel intensity ratios were calculated as the total phospho-Trk signal divided by total number of cells and the data were normalized to the signal from cells in control culture medium.
LM22B-10-induced signaling in vivo
All animal procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals using protocols approved by the Institutional Animal Care and Use Committee at Stanford University. These protocols included efforts to minimize animal suffering and numbers used. Adult male C57BL/6J mice (3 months of age) were randomly divided into vehicle (PBS/Cremophor) and treatment (LM22B-10 in PBS/Cremophor vehicle) groups. Intranasal (IN) administration was performed by applying 10e15 ml into the right naris 3-5 times at 2e4 min intervals, once daily for 1 week. Hippocampal and striatal brain regions were harvested 1 h after the last dose and processed for western blot analysis.
Modified Golgi staining and analysis of spine density
Mice were perfused with 0.9% heparinized saline and the brains were impregnated with Modified Golgi-Cox Staining Solution (developed and provided by Deqiang Jing and Francis Lee, Cornell University) for 8e9 days at room temperature in the dark, as performed previously (Han et al., 2012) . The brains were then rinsed twice with dH 2 O and transferred to 30% sucrose in dH 2 O for 3 days at 4 C, with the solution changed after the initial 12 h. Brains were then coronally sectioned at 150 mm into 30% sucrose in dH 2 O using a vibratome (Leica VT10005). Sections were mounted onto slides coated with 0.3% gelatin in dH 2 O. Once dried, slides were immersed in 40% sucrose in dH 2 O and allowed to dry for 72 h in the dark. Slides were then rinsed three times in dH 2 O for 10 min, immersed in Golgi-Cox Development Solution for 7 min, and rinsed three times in dH 2 O for 10 min. Slides were then dehydrated through graded ethanols followed by Histoclear (HS-200, National Diagnostics), and immediately cover-slipped with DPX mounting medium (EMS). The dendrites and spines of hippocampal CA1 pyramidal neurons were traced using a 100Â objective and Neurolucida. Three dendrites per neuron and three neurons per mouse were analyzed. The spine densities of from second to fourth order dendrites were analyzed using NeuroExplorer (MBF Biosciences).
Statistical analysis
All in vitro and in vivo cellular and morphological analyses were performed in a blinded manner. Based on published work and our previous studies assessing small molecule efficacy, we anticipated greater variability in the drug-treated groups and chose our sample sizes to allow statistical differentiation of groups exhibiting differences of 20% or more. Statistical significance was determined using a one-way Analysis of Variance (ANOVA) and either Dunnett's, Dunn's, or Bonferroni's multiple comparison post-hoc tests with InStat 3 or StatView Software. In cases in which data did not follow a normal distribution, a Mann-Whitney or Kruskal-Wallis test (nonparametric ANOVA) with Dunn's multiple comparison test was applied. p-values reported in the text are for comparisons using post-hoc testing after significant main effects were determined using an ANOVA. Specific post-hoc tests used are provided in the figure legends. Statistical outliers were defined as values that were 3 or more standard deviations from the mean. Using this criterion, only one data point in one experiment was eliminated (Fig. 6I , BDNF response). Results are expressed as group mean ± SEM and statistical significance was set at p 0.05.
Results
Identification and characterization of a small molecule with neurotrophic activity
Our laboratories previously applied in silico screening based on BDNF loop II, thought to be a key domain that mediates binding to and activation of TrkB, to identify non-peptide, small molecule TrkB activators (Massa et al., 2010) . A second screening experiment using a substantially larger compound library was undertaken to broaden the chemical range of active scaffolds and find compounds with improved pharmacologic characteristics, in particular, blood brain barrier penetration. The same BDNF loop II pharmacophore which previously yielded LM22A-4 and other active compounds (Massa et al., 2010) was utilized in an Accelrys Catalyst screen of a new library derived from the Chemnavigator database (now within Sigma-Aldrich, Milwaukee, WI) of~5.5 million commercially available compounds, with an average of~30 conformers tested per compound. 2670 compounds with a low-energy conformer compatible with the pharmacophore and with MW 500 Da were further filtered using Accelrys Cerius2 for compliance with Lipinski criteria (Lipinski et al., 2001 ) and predicted blood brain barrier penetration score. Finally, the highest scoring compound models were visually screened for potential steric interference not accounted for by the pharmacophore model, within a general model of loop II interaction with a shallow receptor region. Of these, 18 compounds were tested for neurotrophic activity using E16 hippocampal neurons under conditions in which survival depends on exogenous BDNF. Four compounds (LM22B À9, -10, -17 and À24) had biological activity that was similar or significantly above BDNF maximal efficacy, 22% of the compounds tested (data not shown). LM22B-10 (MW 485 Da, structure in Fig. 1A ) had the highest efficacy of these and was further characterized for its effects on cell survival, neurite outgrowth, and dendritic spine density.
LM22B-10 exhibited maximum neurotrophic survival activity levels that were higher than those maximally achieved with BDNF (53 ± 7.2% above BDNF at 0.7 nM) and NT-3 (91 ± 8.6% above NT-3 at 0.7 nM) with an EC 50 of 200e300 nM (Fig. 1B, C) . The effects of both BDNF and NT-3 reached a plateau between 0.175 and 0.35 nM (5e10 ng/ml), with stable responses up to the maximum concentration tested (1.85 nM). Survival activity for LM22B-10 reached a plateau by~1000 nM and was stable up to 4000 nM, the maximum concentration tested. Thus, 0.7 nM for BDNF and NT-3, and 1000 nM for LM22B-10 were chosen as standard concentrations for most of the subsequent studies. Cell death, as reflected by TUNEL staining, was reduced by 68 ± 2.3% with BDNF treatment, 64 ± 4.3% with NT-3, and 85 ± 1.4% with LM22B-10 (Fig. 1D ). Maximal survival in the presence of BDNF and NT-3 together approximated that of either NT alone, and remained significantly less than that achieved with LM22B-10 at 48 h in culture (Fig. 1E) . Neurites of E16 hippocampal neurons had average lengths of 20e30 mm at 2 days in vitro and were unaffected by BDNF and NT-3 at concentrations of 0.04e1.85 nM, a range over which maximal effects on survival were reached. In contrast, LM22B-10 at 1000 nM induced neurites of significantly larger average lengths, up to~40 mm (p 0.01 compared to culture medium; Fig. 1F ). LM22B-10 effects on neurite outgrowth began at 125e250 nM, with no significant change between 500 and 1000 nM, and had an apparent EC 50 in the same range as its effects on survival (Fig. 1C,E ). LM22B-10-induced neurites reached maximum lengths within~7 days, while neurite length increased more gradually in hippocampal neurons treated with BDNF, NT-3, or a combination of the two at concentrations that induced maximal survival, approaching the plateau level produced by LM22B-10 over 15e20 days (Fig. 1G) . The median dendritic spine density of hippocampal neurons was also significantly increased with both BDNF and LM22B-10 treatment ( Fig. 1H,I ; p ¼ 0.01 and p < 0.001, respectively, compared to culture medium, p < 0.01 for BDNF versus LM22B-10). Additionally, the cumulative frequency distribution of spines was increased with LM22B-10 (p 0.00002 compared to culture medium and p 0.0003 compared to BDNF; two-sample Kolmogorov-Smirnoff (K-S) test), and showed an increase with BDNF which did not reach significance (p 0.055 compared to culture medium; Fig. 1J ).
LM22B-10 binds selectively to TrkB and TrkC
To address the binding specificity of LM22B-10, three approaches were used: recombinant NT receptor binding of the compound measured by mass spectrometry, cell-based NT competition binding assays, and radioligand inhibition screening of pharmacologically relevant receptors. In the first approach, beadbound receptor extracellular domain/Fc chimeras (TrkA-Fc, TrkBFc, TrkC-Fc and p75 NTR -Fc) were incubated with LM22B-10 (250e2000 nM) and the fraction of bound compound was measured (as in refs (Massa et al., 2010; Pochet et al., 2011; Zehender and Mayr, 2007) ). LM22B-10 bound to TrkB-Fc and TrkC-Fc in a dose-dependent manner, but binding to TrkA-Fc or p75 NTR -Fc was not detected (Fig. 2A) . In addition, cognate NT competition studies were performed using 3T3-cells expressing one of each of the NT receptors. LM22B-10 inhibited binding of BDNF to TrkB-expressing cells (p ¼ 0.0023 for the main effect of the compound on NT binding) and NT-3 to TrkC-expressing cells (p ¼ 0.0003), but had no detectable effect on NGF or BDNF binding to cells expressing TrkA (p ¼ 0.7767) or p75 NTR (p ¼ 0.4356; Fig. 2BeE ). Interestingly, although LM22B-10 binding to TrkB was similar, or perhaps slightly less than, binding to TrkC ( Fig. 2A) , LM22B-10 (1 mM) displaced BDNF (1 nM) nearly completely ( Fig. 2B ) while NT-3 (1 nM) binding was reduced by only~40% (Fig. 2C) . The NT binding regions of TrkB and TrkC are structurally similar however there are significant variances, for example, they differ enough to disallow BDNF binding to TrkC. Thus, differences in E16 mouse hippocampal neurons in culture medium (CM) alone or medium containing BDNF, NT-3 or LM22B-10 (#10) for 48 h. Scale bar, 10 mm. C, Neuron survival dose-response curves for BDNF, NT-3 and LM22B-10. Cell counts were normalized to those achieved with 20 ng/ml (~0.7 nM) BDNF. For BDNF and LM22B-10, values for each concentration were obtained from 12 experiments and derived from 57-67 and 31e69 wells (n). For NT-3, values were obtained from 6 experiments and derived from 39 wells (n). BDNF and NT-3 responses plateau between 0.175 and 0.35 nM (5e10 ng/ml), with stable responses up to the maximum tested, 1.85 nM, LM22B-10 survival activity plateaus at~1000 nM and is stable up to the maximum tested concentration of 4000 nM. D, Quantitation of the fraction of TUNEL-positive/DAPI-staining cells shows that LM22B-10 decreases the number of TUNEL-positive cells as does BDNF and NT-3 with a significantly greater effect of LM22B-10 than the NTs. *p 0.05 versus BDNF and **p 0.01 versus CM. A total of 58e105 fields (n) per condition derived from 4 experiments were counted. E, Quantitation of survival of hippocampal neurons treated with CM, 0.7 nM BDNF, 0.7 nM NT-3, BDNF and NT-3 together, or 1000 nM LM22B-10. Maximal survival is not increased when the NTs are added together. LM22B-10 induces greater survival than BDNF plus NT-3, as well as each individually. A total of 30e60 wells (n) per condition derived from 3-9 assays were counted. ** p 0.01, compared to CM. F, Neurite outgrowth dose responses for BDNF (0.046e1.85 nM), NT-3 (0.046e1,85 nM) and LM22B-10 (0.0325e1000 nM). Cultured E16 mouse hippocampal neurons were treated as indicated for 48 h and immunostained for btubulin III. Neurite outgrowth at each concentration was derived from 88-377 neurites (n) from 6 experiments for BDNF, 135e177 neurites (n) from 5 experiments for NT-3, and, 189e966 neurites (n) obtained from 4 experiments for LM22B-10. ** p 0.01 compared to CM. G, E16 mouse hippocampal neurons were treated with CM, 0.7 nM BDNF, 0.7 nM NT-3 or 1000 nM LM22B-10 for 2, 7, 14 or 21 days and immunostained for b-tubulin III. Neurite outgrowth in 4 experiments from each time point and condition was derived from 96-202 neurites (n) for Day 2, 203e308 neurites (n) for Day 7, 174e300 neurites (n) for Day 14, and 96e165 neurites (n) for Day 21. ***p 0.001 for each condition compared to CM. þp 0.05 and þþp 0.01 for NTs compared to LM22B-10 at different time points. H-I, LM22B-10 increases spine density in vitro. Cultured hippocampal neurons at 14 DIV were transfected with reporter plasmid (EGFP), neurons were treated with 0.7 nM BDNF or 1000 nM LM22B-10 for 24 h and the spine density measured using Neurolucida. At least 10 random confocal images from 3 independent experiments for each condition were measured. H, Photomicrographs of spines on dendrite segments of hippocampal neurons treated small molecule binding, ligand displacement, and even activation of signaling pathways may not be unexpected. The structural correlates of this remain to be investigated. Finally, a radioligand competition binding assay (performed by Cerep, Inc.) was used to evaluate whether LM22B-10 interfered with the binding of 57 Gprotein coupled peptide and non-peptide receptors to their respective ligands, including adenosine, common neurotransmitters and ion channels (see Suppl. Table 1 for the complete list). In this screen, >50% inhibition of control specific binding indicated significant binding by the test compound. LM22B-10 at 10 mM (the standard screening concentration) significantly inhibited only 5HT 5a and the dopamine transporter. Since 10 mM is a high concentration which could lead to non-specific effects, LM22B-10 binding at 1000 nM, a concentration at which the compound produced maximum neurotrophic effects, was evaluated with selected receptors including 5HT 5a and dopamine transporter. At this concentration, LM22B-10 did not significantly inhibit any of the receptors examined (see Suppl. Table 2) . Together these studies demonstrate that LM22B-10 binds to TrkB and TrkC directly and can displace BDNF from TrkB and NT-3 from TrkC. Furthermore, its binding is selective for TrkB and TrkC, and within a standard set of pharmacologically well-characterized receptors, little, if any, significant binding occurs.
LM22B-10 induces biologic activities via TrkB and TrkC
To determine whether the binding selectivity LM22B-10 for TrkB and TrkC correlated with its biological effects, survival responses of 3T3-cells expressing TrkA, B, or C, or p75 NTR , and hippocampal neurons were examined. Adding BDNF or LM22B-10 to serum-free medium did not support survival of the 3T3 parent line, which does not express p75 NTR or Trk receptors (Fig. 3A,B) , nor did it affect survival of 3T3-p75 NTR cells (Fig. 3C) . However, cells engineered to stably express Trks responded substantially to their cognate ligands (Fig. 3A) . LM22B-10 produced a small increase in survival of 3T3-TrkA cells, while cells expressing TrkB or TrkC responded to a substantially greater degree (Fig. 3A) . Quantification revealed that LM22B-10 increased survival in a dose-dependent manner in each cell type (Fig. 3D ): its effects in 3T3-TrkA cells were small with a maximum increase of 62 ± 9% relative to baseline, which was~35% of NGF's effects; substantially larger increases occurred in 3T3-TrkB and 3T3-TrkC cells with respective maximum increases of 123 ± 36% (~78% of BDNF) and 147 ± 35% (~109% of NT-3) relative to baseline. Since NT-p75 NTR binding may stimulate anti-survival mechanisms under some circumstances and interactions between Trks and p75 NTR may influence the outcomes of ligand binding, it was of interest to further investigate the potential role of the differences in binding to p75 NTR of LM22B-10 relative to the NTs in the differential survival responses observed in neurons. To begin to examine this question, p75 NTR was expressed in 3T3-TrkB and -TrkC cells (Fig. 3E) which were then exposed to BDNF, NT-3 or LM22B-10 in serumfree medium. Expression of p75 NTR in both 3T3-TrkB and 3T3-TrkC cells significantly reduced the increase in survival that occurs in the presence of BDNF and NT-3 respectively (each p 0.05 for p75 NTR vs. control plasmid), but had no effect on LM22B-10 responses (Fig. 3F, G) . It is clear, particularly in the case of TrkB cells (Fig. 3F) , that if the response of TrkB/p75 NTR -expressing cells to BDNF was considered to be the maximum neurotrophic response, then the response to LM22B-10 would be substantially greater (56 ± 20% increase). These results are consistent with the involvement of p75 NTR signaling in the observed differences between the NTs and LM22B-10 in the support of neuronal survival, though other factors may contribute.
To further examine whether LM22B-10's neurotrophic activity was dependent on its activation of TrkB and TrkC, survival responses were assessed in the presence of the kinase inhibitor K252a. K252a substantially inhibited the survival effects of the NTs in TrkB and TrkC cells (Fig. 3H, I ), and had a similar effect on LM22B-10-induced survival, suggesting that the compound's activities depend on Trk kinase activation. Of note, although K252a has also been shown to block mixed-lineage kinases, thereby inhibiting JNK activation and activating AKT and ERK through the Src pathway (Roux et al., 2002; Walter et al., 2011) , K252a alone did not affect survival in this cellular system. BDNF effects on survival in hippocampal cell cultures were nearly completely inhibited by K252a, whereas the LM22B-10 response was inhibited by~60% (Fig. 4A) . Though this finding could indicate non-Trk mediated effects of LM22B-10, there are potential Trk mechanisms that are insensitive to K252a, for example, truncated TrkB isoforms, which completely lack tyrosine kinase activity, have been reported to support NTmediated calcium signaling that is insensitive to K252a (Rose et al., 2003) .
The finding that survival responses to BDNF and NT-3 were reduced in 3T3-cells co-expressing p75 NTR and Trks, but were unaffected by LM22B-10 suggested that LM22B-10's greater effects on neuronal survival and/or neurite outgrowth than those caused by NTs could be due, at least in part, to its lack of engagement of p75 NTR . This possibility, and the dependence of LM22B-10 effects on Trks, was further explored in a neuronal context by analyzing whether the effect of NTs or LM22B-10 on survival and neurite outgrowth were affected by inhibiting TrkB or TrkC via anti-Trk antibodies, or by up-or down-regulating p75 NTR in hippocampal neurons. Applying antibodies specific to TrkB or TrkC to hippocampal neurons partially inhibited the survival promoted by their cognate NT ligands and by LM22B-10 (each p 0.001 for TrkB and TrkC antibody vs. control; Fig. 4B, C) . Neurite outgrowth, which was not increased at 2 DIV in the presence of BDNF or NT-3, was unchanged by TrkB or TrkC antibodies (not shown), but both antibodies decreased the promotion of neurite length seen with LM22B-10 (p 0.01 vs. non-immune serum), consistent with compound action through each receptor (Fig. 4D) . Interestingly, a p75 NTR antibody had the opposite effect on neurite outgrowth in the presence of LM22B-10, causing a significant increase relative to non-immune serum treatment (p 0.01), which was not observed with the NTs (Fig. 4D) . The presence of the p75 NTR antibody significantly promoted survival above that induced by the NTs and LM22B-10 (p 0.05 for BDNF versus non-immune serum; p 0.001 for NT3 and LM22B-10 vs. non-immune serum; Fig. 4E ), consistent with a previous report of reversal of NT-mediated death with a p75 NTR antibody (Friedman, 2000) . Furthermore, p75 NTR siRNA treatment of hippocampal neurons that resulted in an~86% knockdown of p75 NTR protein (Fig. 4F ) significantly increased survival with NT and LM22B-10 exposure (p 0.001 vs. control siRNA) (Fig. 4G ). p75 NTR knockdown also increased neurite outgrowth at 2 DIV in response to LM22B-10 (p 0.05 versus control siRNA) similar to that observed with p75 NTR antibody (Fig. 4H ). This effect was not observed with the NTs. Interestingly, the presence of BDNF and/or NT-3 significantly inhibited LM22B-10's enhancement of neurite development (Fig. 4I ) and survival (data not shown).
with BDNF or #10 or untreated (CM). Scale bar, 10 mm. I-J, Quantitation of dendritic spine density (I; **p ¼ 0.011 and ***p < 0.001 versus CM, Mann Whitney test) and cumulative frequency distribution (J, p ¼ 0.055, BDNF compared to CM; p 0.000016, LM22B-10 compared to CM; p 0.00035, LM22B-10 compared to BDNF; K-S test). Unless otherwise noted, statistical significance for each analysis was determined using ANOVA with post-hoc Dunnett or Bonferroni multiple comparison test.
Possible mechanisms of this inhibition include direct competition at TrkB and TrkC, and/or inhibitory p75 NTR or Trk signaling that is not induced by LM22B-10. The biological effects of some neurotrophic agents may occur via G protein-coupled receptor (GPCR)-mediated transactivation of Trks involving Src family kinases (Daub et al., 1997; Lee and Chao, 2001; Lee et al., 2002; Luttrell and Luttrell, 2004) . Trk activation by this mechanism has been reported for adenosine via the adenosine A 2A receptor, and PACAP via its receptor PACR1 (Lee and Chao, 2001; Lee et al., 2002; Shi et al., 2010) . This raised the possibility that LM22B-10 might activate a GPCR or another receptor, which then activates TrkB/TrkC. To evaluate this possibility, the effects of the Src inhibitor PP2 on survival, neurite outgrowth and TrkB phosphorylation of hippocampal neuron cultures treated with LM22B-10 or NTs was determined. PP2 (10 mM) did not affect neuron survival mediated by NTs or LM22B-10 or neurite outgrowth induced by LM22B-10 (Fig. 4J, K) . In addition, PP2 decreased tyrosine phosphorylation of TrkB and TrkC elicited by adenosine and PACAP27, but did not affect that induced by LM22B-10 or the NTs (Fig. 4L) . Together, these results suggest that TrkB and TrkC activation by LM22B-10 is not due to a Src kinase-mediated Trk transactivation mechanism.
LM22B-10 promotes neurite outgrowth in an inhibitory environment
The central nervous system (CNS) undergoes limited repair after injury, due in part to the presence of inhibitors of neurite outgrowth that prevent axonal regeneration, including myelinassociated glycoprotein (MAG) and chondroitin sulfate proteoglycans (CSPGs) (Berry, 1982; McKerracher et al., 1994; Niederost et al., 1999) . NTs may or may not facilitate axonal growth in the presence of myelin-component inhibitors (Spencer et al., 2008; Wang et al., 2002; Williams et al., 2005) depending upon the interplay of outgrowth-supporting Trk-mediated signaling and growth cone collapse-promoting p75 NTR -mediated signaling, and varying with cell type and physiologic state (Naska et al., 2010) . A prior study found that a peptide designed to activate TrkB without effects on p75 NTR could reverse MAG inhibition of cerebellar neurite outgrowth, while BDNF did not (Williams et al., 2005) , suggesting that isolated stimulation of Trks may support process outgrowth in an inhibitory environment. The activation of Trks and increases in neurite outgrowth induced by LM22B-10 without apparent engagement of p75 NTR suggested that it might also have this effect. To test this hypothesis, LM22B-10 effects on neurite outgrowth of cultured hippocampal neurons (2 DIV) were assessed in the presence of MAG or CSPG (Fig. 5A, B) . Under these conditions BDNF and NT-3 had no effect on neurite outgrowth in culture medium alone (similar to Figs. 1E, 4D and H), while each appeared to produce a small sparing effect on the decrement in outgrowth observed in the presence of CSPG (30 ± 6% over culture medium for BDNF, 23 ± 7% for NT-3), and were each entirely ineffective in the presence of MAG (Fig. 5B) . In marked contrast, LM22B-10 significantly increased neurite length in the inhibitory environments: 92 ± 8% with CSPG and 57 ± 6% with MAG (both p 0.001). These findings suggest that LM22B-10 neuritogenic signaling is resistant to p75 NTR -coupled inhibition.
LM22B-10 induces patterns of Trk and downstream signaling activation that are distinct from those of BDNF and NT-3
To begin to investigate the differences in biologic activity profiles between LM22B-10 and the NTs, their patterns of induction of Trk and downstream effector phosphorylation were examined. In TrkA-3T3 cells, LM22B-10 did not induce detectable phosphorylation of TrkA at Y490 or Y791, or of AKT or ERK1/2, in marked contrast to NGF (Fig. 6A) . In 3T3-TrkB cells, BDNF, at a concentration stimulating its maximal biological activity, increased TrkB phosphorylation at Y515, Y705, and Y817, and promoted phosphorylation of ERK, AKT, and PKC. LM22B-10, at a concentration that induces its maximal neurotrophic activity (1000 nM), also induced detectable TrkB phosphorylation at each of these sites as well as AKT, ERK and PKC phosphorylation, though to a substantially lesser degree than BDNF (Fig. 6B, C) . The pattern of lesser TrkB activation induced by LM22B-10 relative to BDNF was also observed using TrkB immunoprecipitation followed by phospho-tyrosine detection with the pY99 antibody (Fig. 6D, E) . These results were similar to those previously observed for the TrkB partial agonist LM22A-4 NTR antibodies for 48 h. For each condition 33e338 neurites (n), derived from 3 experiments were assessed; ** p 0.01 compared to CM plus nonimmune serum; þþþp 0.001 compared to CM. E, Survival of hippocampal neurons treated with CM, 0.7 nM BDNF, 0.7 nM NT-3 or 1000 nM LM22B-10 with or without p75 NTR antibody. 15e16 wells (n), derived from 4 experiments were assessed; *p 0.05 and ***p 0.001 compared to the respective CM plus non-immune serum group; þþþp 0.001 compared to CM. F-H, Hippocampal neurons were transfected with control siRNA or p75 NTR siRNA. F, Representative Western blot demonstrating that p75 NTR siRNA decreases p75 NTR expression by~86% relative to control. G, Survival analysis of hippocampal neurons treated with CM, BDNF, NT-3 or LM22B-10 with control siRNA or p75 NTR siRNA. p75 NTR siRNA causes a significant increase in survival with all treatments. 18 wells (n), derived from 3 experiments were assessed; *p 0.05 and **p 0.01 compared to the respective control siRNA group; þþþp 0.001 compared to CM. H, Neurite outgrowth analysis of hippocampal neurons treated with CM, 0.7 nM BDNF or 1000 nM LM22B-10 with control siRNA or p75 NTR siRNA for 48 h. For each condition 75e323 neurites (n), derived from 3 experiments were assessed; * p 0.05 compared to the respective control siRNA group; þþþp 0.001 compared to CM. I, Neurite outgrowth of cells treated with CM, 0.7 nM BDNF, 0.7 nM NT-3 with or without 1000 nM LM22B-10 as indicated. Addition of NTs alone or in combination decreased the neurite length promotion induced by LM22B-10. Neurite outgrowth for each condition was derived from 83-531 neurites (n) obtained from 3 separate experiments; * p 0.05 and *** p 0.001 compared to LM22B-10. Statistical significance was determined using an ANOVA with a post-hoc Bonferroni multiple comparisons test in A-H and a post-hoc Dunnett's multiple comparisons test in I. J-L, Cultured E16 hippocampal neurons treated with CM, BDNF, NT-3 or LM22B-10 without or with 10 mM PP2 for 48 h (J, K) and 1 h (L). J, Survival analysis: PP2 did not significantly affect survival in any of the treatment conditions; 16 wells (n), derived from 4 experiments were assessed; þþp 0.01 compared to CM. K, Neurite outgrowth analysis. For each condition 89e750 neurites (n), derived from 3-6 experiments were assessed; þþp 0.01 compared to CM in J and K. L, For Western analyses, the ratios of phospho-anti-Trk Y490 to total panTrk were determined and normalized to the CM group. Samples run in Lanes 1e6 were from cultures that were not treated with PP2, those run in Lanes 7e12 were treated with PP2. Other treatments are as follows, Lanes 1,7: CM; Lanes 2, 8: BDNF; Lanes 3,9: NT3; Lanes 4,10: LM22B-10; Lanes 5,11: adenosine; Lanes 6,12: PACAP. Quantitation of BDNF and NT3 is not shown. n ¼ 6 independent protein preparations measured on 18 western blots. Statistical significance was determined using an ANOVA with a post-hoc Dunnett's test in J-L or Student's t-test in L for comparison between with and without PP2 groups. *p 0.05 comparing with and without PP2. þp 0.05 compared to CM. (Massa et al., 2010) . TrkB activation was further evaluated by direct measurement of kinase activity in TrkB immunoprecipitates, which demonstrated significant activation induced by both BDNF and LM22B-10 (p 0.01 and 0.05, respectively, versus culture medium; Fig. 6F ).
TrkB phosphorylation at Y515 promotes recruitment of the adaptor protein Shc, which is crucial for NT-dependent cell growth and differentiation (Reichardt, 2006) . Previous studies demonstrated that BDNF and LM22A-4, a small molecule TrkB ligand, induced TrkB activation and Shc recruitment in human cementoblast-like cells (Kajiya et al., 2014) . In the present study using the same cell system, LM22B-10 promoted Shc recruitment to TrkB (Fig. 6G ) consistent with its triggering activation of the receptor and with the activation of Ras-MAPK and PI3K-AKT signaling induced by the compound (Fig. 6C) .
Although LM22B-10 bound to the extracellular domains of TrkB and TrkC, induced TrkB/C phosphorylation and downstream signaling, had its biological effects inhibited by TrkB/C extracellular domain antibodies, and activated TrkB/C independently of Src kinase-mediated transactivation, the possibility remained that the compound binds to an unknown target that is capable of inducing a non-Src-dependent transactivation of Trk. To address this possibility, the effects of LM22B-10 on Trk phosphorylation were examined in HEK-293 cells expressing full-length wild-type TrkB or chimeric TrkA/B receptors (Perez et al., 1995; Zaccaro et al., 2001 ). In the TrkA/B chimera 1.4B, the extracellular domain of TrkA is fused with the intracellular domain of TrkB, and in the chimeric receptor 4.1B the TrkB IgG-C2 domain, which is required for BDNFTrkB activation (Zaccaro et al., 2001) , is replaced by the TrkA IgG-C2 region. Western blot analysis using anti-Trk 674/675 , which recognizes phosphorylated tyrosine residues at the catalytic domain of Trks indicating Trk kinase activity, was performed on cells expressing these constructs and treated with NGF (0.7 nM), BDNF (0.7 nM) or LM22B-10 (1000 nM) (Marsh et al., 2003) . In HEK-293 cells expressing full-length WT TrkB, BDNF and LM22B-10 triggered increased tyrosine phosphorylation, while NGF did not (Fig. 6H,I ). In contrast, in cells expressing the TrkA/B chimeric receptors, NGF promoted phosphorylation, but BDNF and LM22B-10 did not (Fig. 6J,K) . These findings suggest that LM22B-10 activation requires the TrkB extracellular domain and are not consistent with Trk transactivation studies (Lee and Chao, 2001; Lee et al., 2002; Shi et al., 2010) in which transactivation persists in the presence of the TrkA extracellular chimera. Interestingly, these findings also indicate that the IgG-C2 domain or a nearby region may be involved in LM22B-10-mediated receptor activation.
While LM22B-10 induced a TrkB phosphorylation pattern that differed from that of BDNF, it induced a pattern very similar to that of NT-3 at homologous Trk sites in 3T3-TrkC cells (Fig. 6L,M) . A plot of mean NT versus compound phosphorylation signal ratios for each cell type (Fig. 6N ) further illustrated the close relationship between LM22B-10-induced patterns and those associated with NT-3 (mean slope ¼ 1.51, r 2 ¼ 0.78) and variances with BDNF responses (mean slope ¼ 0.032, r 2 ¼ 0.018). Interestingly, the pattern of phosphorylation induced by LM22B-10 was similar in TrkC and TrkB cells (compare Fig. 6C, M) . LM22B-10 might differentially stimulate receptor activation and signaling in the presence of multiple receptors found in a neuronal context, or there might be significant differences in signaling kinetics relative to the NTs. Therefore, it was of interest to examine Trk and its downstream signaling intermediates over time following stimulation in hippocampal neurons. BDNF exposure produced significantly greater phosphorylation of TrkBY 515 , TrkBY 705 and TrkBY 817 than that induced by LM22B-10, with BDNF producing near plateau levels within 10 min, and LM22B-10 requiring 60 min to achieve significant increases (Fig. 7A, DeF) . Exposure to NT-3, which activates both TrkB and TrkC (Ryden and Ibanez, 1996) (Fig. 7B ,G) resulted in greater phosphorylation of TrkC at sites Y516 and Y820 relative to the compound, though this difference was not statistically significant (Fig. 7B,H) . Similar to TrkB, there was an apparent delay of significant TrkC phosphorylation levels of~60 min for LM22B-10 while NT-3 produced significant increases within 10 min. LM22B-10 significantly increased phosphorylation of AKT and ERKs above baseline with similar kinetics as BDNF and NT-3 (Fig. 7C, I , J). In response to the NTs, ERK1/2 activation was significantly greater than with LM22B-10 but AKT activation was not (Fig. 7I, J) . Phosphorylation of PKC occurred to a similar degree amongst the treatments (Fig. 7C, K) . Thus, stimulation of neurons with concentrations of LM22B-10 which induce maximal survival and neurite outgrowth produced less phosphorylation than the NTs at TrkB Y515 /TrkC Y516 , similar to the pattern observed in 3T3-TrkB cells (Fig. 6C, K) , as well as similar or lesser phosphorylation of AKT and ERKs, similar to the responses of neurons to LM22A-4, a first generation compound which binds to and activates TrkB but not TrkC (Massa et al., 2010) . In addition, the kinetic profiles for TrkB Y490 , AKT and ERK phosphorylation are highly similar between LM22B-10 and LM22A-4. Of note, a modest and similar increase in phosphorylation of PKC was detected in response to both NTs and LM22B-10 (Fig. 7K) , consistent with their promotion of phosphorylation at TrkB Y817 /TrkC Y820 which are coupled to this pathway via PLCg activation (Reichardt, 2006) . Immunostaining in hippocampal cultures showed no apparent differences in localization of p-TrkB or pTrkC between NT-and LM22B-10-treated cells. Significant increases in pTrkB and signaling with 10% FBS to 50e60% confluence, exposed to NTs or LM22B-10 (#10) for 48 h in serum free medium containing 50% PBS and 50% DMEM, incubated in 50% PBS/50% DMEM without NTs or LM22B-10 for 6 h, and finally exposed to 20 ng/ml (0.7 nM) NT or 1000 nM LM22B-10 in serum-free DMEM for 1 h. Cell lysates were analyzed by immunoblotting, immunoprecipitation, and kinase activation assays. Representative Western blots show contiguous lanes and white spaces separate panels from different gels; total protein bands are re-probed from the corresponding phospho-lanes. Immunoblots were quantitated by determining the ratios of phospho(p)-protein over total protein and normalized to the CM group. A, In 3T3-TrkA cells, NGF induced TrkA, AKT and ERK phosphorylation while LM22B-10 did not. B, C, In 3T3-TrkB cells, BDNF and LM22B-10 induced TrkB, AKT, ERK and PKC phosphorylation. For each determination, n ¼ 10e14 independent protein preparations were measured on 20e28 western blots (each sample run in duplicate and the results averaged). Statistical significance was determined using an ANOVA with post-hoc Dunn's multiple comparisons test. * p 0.05, ** p 0.01 and *** p 0.001 compared to CM. D, E, F, 80e100 mg/ml of extracted protein was immunoprecipitated with TrkB antibody, and half of the protein was retained for Western blotting and the other half saved for kinase activity determination. D, E, Western blot membranes were probed with either pY99 or TrkB antibody. Bands were analyzed using UN-SCAN-IT software and the ratio of pY99 to TrkB was normalized to CM. n ¼ 13 protein preparations and 26 western blots, each preparation was run in duplicate and the normalized values averaged. F, Kinase assay was performed as described in Methods, n ¼ 10 independent protein preparations with values from two immunoprecipitations of each sample averaged. Each treatment was compared to CM using the Mann-Whitney U test (*p 0.05, **p 0.01, ***p 0.001). G, Human cementoblast-like cells were treated with BDNF (0.7 nM) or LM22B-10 (1000 nM) and protein extracts were immunoprecipitated with TrkB antibody. Western blot membranes were probed with either Shc or TrkB antibody and the ratio of Shc to TrkB was normalized to CM. n ¼ 13 protein preparations and 26 western blots, each preparation was run in duplicate and the normalized values averaged. Each treatment was compared to CM using the Mann-Whitney U test (*p 0.05, ***p 0.001). H-K, HEK-293 cells were transfected with TrkB full length plasmid (TrkB-WT), TrkA/B chimeras 1.4B (TrkA/B-1.4B) and TrkA/B chimeras 4.1B (TrkA/B-4.1B) then exposed to 0.7 nM indicated NTs or 1000 nM LM22B-10. Cell lysates were analyzed by immunoblotting. I-K, Western analyses were quantitated by determining the ratios of pTrk over total Trk protein and normalized to the CM group. For TrkB-WT, n ¼ 22 independent protein preparations. For TrkA/B-1.4B, n ¼ 13 independent protein. For TrkA/B-1.4B, n ¼ 8 independent protein preparations. Statistical significance was determined using an ANOVA with post-hoc Dunn's multiple comparisons test. **p 0.01 and ***p 0.001 compared to CM. L,M, In 3T3-TrkC cells, NT-3 and LM22B-10 induce TrkC, AKT and ERK phosphorylation, but not PKC. For each determination, n ¼ 10e14 independent protein stimulated by both BDNF and LM22B-10 were observed, with a lesser induction by LM22B-10, which reached statistical significance above baseline for Y817 (p 0.05) but did not reach significance for Y515 (Fig. 7L, M, N) . TrkC activation studies in hippocampal neuron cultures showed significant increases in pTrkC signal stimulated by LM22B-10 and NT-3 at both Y516 (p 0.01) and Y820 (p 0.01 for NT-3 and p 0.05 for LM22B-10), with apparent lesser inductions by LM22B-10 (Fig. 7L, O, P) . Together, these studies reveal similarities between LM22B-10 and LM22A-4 compounds, and differences relative to the NTs with respect to the initiation and extent of signaling suggesting the possibility of discrete activation mechanisms utilized by different ligand classes.
AKT, ERK and PLCg activation contribute to neurotrophic activity of LM22B-10
Since LM22B-10 produces less or similar acute AKT and PKC activation compared to the NTs, and significantly less ERK activation, while exhibiting greater effects on survival and neurite outgrowth, the possibility of the involvement of other Trkdependent signaling, and the question of the role of AKT, ERK and PLCg activations in the compound's biologic effects arise. In TrkBand TrkC-expressing 3T3 cells and hippocampal neurons, NT and LM22B-10 survival-inducing activities were significantly reduced by LY294002, a selective inhibitor of PI3K (an upstream activator of AKT); PD98059, a MAPKK inhibitor (an upstream activator of ERK); and U73132, a PLCg inhibitor (an upstream activator of PKC) (Fig. 8A, B ). LY294002 and U73132 each reduced LM22B-10 effects on survival of both 3T3-TrkB and eTrkC cells to 1.5e1.8 times the culture medium background (p 0.01 for TrkB cells; p 0.05 for TrkC cells), while PD98059 was more effective (p 0.01 for TrkB and TrkC cells; Fig. 8A ). This pattern of signal reduction was distinct from that observed with the NTs possibly due to differences between the NTs and LM22B-10 with respect to mechanisms of Trk activation, and/or, may indicate that LM22B-10 acts through additional targets. In addition, the inhibitors were generally less effective in reducing BDNF/TrkB cell survival to baseline than they were with NT-3/TrkC cells, possibly reflecting the stronger activation of downstream signaling afforded by BDNF in TrkB cells. In contrast to TrkB-3T3 cells, the inhibitors reduced BDNF's survival effects on hippocampal neurons to a greater extent than those of LM22B-10. Interestingly, the abundant short-latency neurite outgrowth of hippocampal neurons induced by LM22B-10 is inhibited by LY294002 and U73132 (both p 0.001), but not PD98059 (Fig. 8C) , suggesting that the augmentation of neurite outgrowth produced by the compound may be independent of the activation of ERKs, and could involve other non-Trk targets.
LM22B-10 activates TrkB, TrkC, AKT and ERK in vivo
To further examine the biologic effects of LM22B-10 and determine its suitability as a therapeutic candidate, the blood brain barrier penetration of the compound was determined via different routes of administration. Brain levels in mice were measured by LC-MS/MS 0.5e8 h after intraperitoneal (IP), oral gavage (OG), and IN administration. Following IN administration at 5 mg/kg, brain levels reached~45 nM (Fig. 9A) , a concentration that showed neurotrophic activity in vitro. IP injection produced brain levels in the 600e1500 nM range 1e8 h after administration (Fig. 9B) , while OG administration resulted in a similar peak at 3 h and produced levels in the~800 nM range at 8 h. The lowest dose that produced concentrations in brain which were similar to those which produced biologic activity in vitro (5 mg/kg IN) and a 10-fold lower dose (0.5 mg/kg) were then utilized for evaluation of LM22B-10 activation of Trk signaling in C57BL/6J mice. Following 7 days of once daily IN administration to adult mice with harvesting 1 h after the last dose, quantitative western blotting revealed dosedependent activation of TrkB and TrkC, as well as AKT and ERK in the hippocampus (overall signaling vs. dose, F 2,117 ¼ 31.882, p < 0.0001) (Fig. 9C ) and striatum (overall signaling vs. dose, F 2,117 ¼ 16.453, p < 0.0001) (Fig. 9D) . This result is consistent with in vivo target engagement by LM22B-10, and given the low dose and small cell populations within each sampled brain area that express TrkB and TrkC, may indicate a particularly robust signaling response.
3.8. LM22B-10 activates synaptic TrkB and TrkC and increases preand post-synaptic proteins and spine density in aged mice Marked decreases in hippocampal neuron dendritic spine density occur in normal aging, are associated with memory dysfunction (Lahiri et al., 2005; von Bohlen und Halbach et al., 2008; von Bohlen und Halbach et al., 2006) , and can be reversed by BDNF (Kramar et al., 2012; Lynch et al., 2008; Rex et al., 2007) . Since LM22B-10 increased spine density in vitro, and since it was found to engage its signaling targets in brain tissue, it was of interest to determine whether it might decrease spine loss in aged mice. Male 15e17 month old C57Bl/6J mice were administered LM22B-10 at 50 mg/kg IP and 5 mg/kg IN simultaneously to maximize compound brain levels, once daily for 30 days, and, 1 h after the last dose, brains were harvested. Hippocampal synaptosomes from these mice showed increased phosphorylation at TrkB Y817 and TrkC Y820 in response to LM22B-10 (both p 0.05 versus vehicle), again consistent with in vivo CNS target engagement (Fig. 10A, B) . LM22B-10 also increased levels of the pre-and post-synaptic proteins synaptophysin and PSD95 (both p 0.05 versus vehicle; Fig. 10C , D). Consistent with these synaptic marker results, on basal and apical dendrites of hippocampal CA1 neurons in these aged mice, LM22B-10 increased spine cumulative frequency distributions (p 3 Â 10 À8 for apical and p 7.5 Â 10 À6 for basal versus vehicle;
two-sample K-S test) and density (p 0.01 and p 0.05, respectively; Fig. 10E, F, G) . The functional consequences of these biochemical and structural changes remain to be explored.
Discussion
Characterization of LM22B-10 has revealed several significant similarities and differences with NT action, and with the actions of previously described small molecule Trk ligands. The most striking of these are the findings that LM22B-10 promotes cell survival and accelerates neurite outgrowth in significant excess of that induced by the native NTs, and produces neurite growth resistant to inhibitory signals, despite apparently low levels of canonical NT signaling pathway activation. Multiple lines of evidence suggest that LM22B-10 functions as an active TrkB and TrkC ligand, including: detection of direct binding to TrkB and TrkC; inhibition by the compound of BDNF and NT-3 binding to their cognate receptors; the dependence of trophic activity on TrkB or TrkC expression; kinase inhibitor K252a inhibition of neurotrophic activities; inhibition of activity by blocking antibodies specific to the preparations measured on 20e28 western blots (each sample run on duplicate blots and the results averaged). Statistical significance was determined using an ANOVA with posthoc Dunn's multiple comparisons test. The findings that LM22B-10 produces neurotrophic effects that are not identical to those of NTs (relatively greater effects on survival and neurite outgrowth; neurite outgrowth on inhibitory substrates) and that its signaling dynamics differ from those of NTs (slower Trk activation and reduced but significant activation of downstream signaling) raise two mechanistic possibilities. First, LM22B-10, as a compound designed to correspond to only one of multiple NT domains interacting with Trk, and not capable of binding to p75 NTR , activates Trk receptors through mechanisms that are, at least in part, different from those triggered by NTs. At this point relatively few Trk partial agonists and/or allosteric contiguous lanes, total protein images were reprobed from the corresponding phospho-lanes and white space separates panels from different gels. L-P, Immunohistochemical analysis of TrkB and TrkC phosphorylation in hippocampal neurons. Cultured E16 hippocampal neurons were incubated with 0.7 nM BDNF, 0.7 nM NT-3 or 1000 nM LM22B-10 for 1 h. Cells were then immunofluorescently stained with the indicated phospho-specific Trk antibodies. Total fluorescence intensity was quantitated using UN-Scan-it software; ratios of total fluorescence intensity over total cell numbers were calculated. L, Representative immunostaining images. Scale bar, 10 mm. M-P, Immunostaining quantitation. For each determination, n ¼ 15e18 fields total derived from 3 independent experiments. Statistical significance was determined using an ANOVA with post-hoc Dunn's multiple comparisons test. *p 0.05, **p 0.01, ***p 0.001 compared to CM.
modulators exist, thus, the limited characterization available limits any general expectation regarding the biological and signaling repertoire expected of such compounds. An important second possible mechanism is that LM22B-10 might bind to and activate unidentified non-Trk targets that are capable of transactivating Trks and promoting their downstream signaling. This possibility was made less likely by our inability to detect known mechanisms involving Src-dependent Trk transactivation, and the dependence of LM22B-10 TrkB activation on the presence of the TrkB extracellular domain. Together, these findings suggest that binding of LM22B-10 to TrkB and TrkC promotes biologic activities to a large, but not necessarily exclusive extent, through Trk receptors and coupled activation of signaling pathways. As is the case for all growth factor ligands, all small molecules and all drugs, alternative mechanisms cannot be completely ruled out and additional target studies will be required. Both binding and biologic activities appeared to be relatively selective for TrkB and TrkC. Though LM22B-10 produced a small increase in survival of TrkA-expressing cells, it did not detectably bind to, or alter NT binding to TrkA. These findings might be due to the greater sensitivity of detection of biological activity versus detection of ligand binding. Similarly, activation of three primary downstream signaling intermediates (PI3K/AKT, MAPK/ERK and PLCg/PKC) was not observed in cells expressing TrkA alone. Thus, the minor bioactivity associated with TrkA expression might be due to compound-induced signaling below detectable levels, though alternative mechanisms, including action through an unidentified non-Trk target, remain possible. Further, LM22B-10 did not bind to p75 NTR , and there was no trophic effect in p75 NTR -3T3 cultures. With expression of individual Trks, in a non-neuronal context Fig. 8 . LM22B-10's effects on survival depend on downstream signaling. A, 3T3-TrkB and 3T3-TrkC cells were incubated with 0.7 nM BDNF or 1000 nM LM22B-10 for 72e96 h in the presence or absence of the PI3K inhibitor LY294002 (LY, 10 mM), MAPKK inhibitor PD98059 (PD, 50 mM) or PLCg inhibitor U73132 (1 mM). Cell survival was assessed using ViaLight. B, Survival of E16 hippocampal neurons incubated with 0.7 nM BDNF or 1000 nM LM22B-10 for 48 h in the presence or absence of LY, PD or U73132. For each survival determination, n ¼ 14e26 wells derived from 7-11 independent experiments were analyzed. C, Neurite outgrowth of E16 hippocampal neurons incubated with 0.7 nM BDNF or 1000 nM LM22B-10 for 48 h in the presence or absence of the K252a (200 nM), 10 mM LY, 50 mM PD, or 1 mM U73132. For each condition, 39e196 neurites (n), derived from 3 experiments were assessed. Statistical significance was determined using an ANOVA with post-hoc Dunnett's multiple comparisons test. *p 0.05, **p 0.01 and ***p 0.001 compared to CM with either BDNF or #10. and absent p75 NTR , downstream signaling patterns produced by LM22B-10 were significantly different from those induced by BDNF/TrkB, but similar to NT-3/TrkC (Fig. 6) . However, in neurons, compound-induced acute TrkB, TrkC, ERK1/2 and AKT signaling were substantially lower than that produced by either BDNF or NT-3. This finding is similar to our previous work characterizing LM22A-4, a small molecule ligand that binds only to TrkB and functions as a partial agonist with maximal neurotrophic and TrkB signaling activities lower than those triggered by BDNF (Massa et al., 2010) , in contrast to LM22B-10. Detailed kinetic analysis of responses in hippocampal neurons revealed delayed activation of TrkB by LM22A-4 relative to that stimulated by BDNF while kinetics of AKT and ERK1/2 were similar between these two compounds up to 4 h after dosing. In the present study, LM22B-10 presents a similar kinetic profile. The finding that neurite outgrowth is resistant to MAPKK inhibition with PD98059 is of particular interest. This result was unexpected, as ERK1/2 activation may be associated with neurite outgrowth and PD98059 has been found to inhibit neurite growth in some stimulation paradigms (Pang et al., 1995; Sjogreen et al., 2000) ; however the effects of MAPK inhibition may vary, and may even be reversed, depending on the state of the cells and stimuli utilized (Althini et al., 2004; Wiklund et al., 2002) . Since LM22B-10 produces neurite-growth effects that are substantially accelerated relative to those caused by BDNF or NT-3, even in combination, while at the same time stimulating lower levels of activation of TrkB and TrkC and their primary downstream signaling modules, other non-classical mechanisms may be involved. These could include quantitatively or qualitatively novel TrkB/TrkC signaling patterns, due to: qualitative differences in receptor activation or deactivation kinetics, or turnover, in particular over longer periods of time; activation ratios; or recruitment of parallel/non-canonical pathways, resulting in synergistic neurotrophic effects not normally occurring with BDNF/NT-3 signaling. In addition, binding of LM22B-10 to TrkB/TrkC in the absence of p75 NTR binding and its anti-trophic effects, might alter overall signaling patterns resulting in a net increase in neurite outgrowth, suggested by the further enhancement of neuritogenesis and survival with p75 NTR antibody blockade and knock-down, and resistance of LM22B-10 neurotrophic activity to the introduction of p75 NTR expression. Finally, though perhaps less likely, LM22B-10 might bind to one or more unknown targets distinct from TrkB/ TrkC that, by coincidence, have a substantial impact on neurite outgrowth. Further analysis of LM22B-10/Trk kinetics, interactions with p75 NTR , possible non-Trk targets and downstream signaling dependencies will be needed to construct a detailed model of LM22B-10 action. Another feature of LM22B-10 biological activities of potential practical importance, consistent with its initiation of novel signaling patterns, is its overcoming of neurite inhibitor effects of MAG and CSPG, which is not achieved by the native NTs. Given the C, D, LM22B-10 or saline control was administered intranasally to 3 month old mice at the indicated dosages for 7 days. Western blots of extracts of hippocampus (C) and striatum (D) were quantitated by determining the ratios of phospho (p)-protein over total protein and normalized to respective CM groups; n ¼ 5 mice, with three independent western blots averaged per animal. Statistical significance was determined using an ANOVA with post-hoc Dunn's multiple comparisons test. *p 0.05 and **p 0.01 compared to saline.
suggested roles for MAG and CSPG in inhibiting neurite outgrowth in spinal cord injury (SCI) (Busch and Silver, 2007; Giger et al., 2008) , it will be of interest to determine if LM22B-10 or its derivatives might promote neurite outgrowth in vivo in SCI models.
Previous work has led to the development of small molecules capable of functioning as ligands that activate specific Trk receptors (Jang et al., 2010a (Jang et al., , 2010b (Jang et al., , 2007 Maliartchouk et al., 2000; Massa et al., 2010; Scarpi et al., 2012) , and activation of TrkA and TrkB by amitriptyline has been reported (Jang et al., 2009 ). To our knowledge, LM22B-10 constitutes the first small molecule capable of preferentially activating TrkB and TrkC, and also the first to have neurotrophic activity substantially exceeding that of the native NTs. The structural bases of Trk activation by these various small molecules remain unclear. Some have been reported to promote receptor dimerization, and evidence has been presented for different Trk binding sites for several molecules, both intra-and extracellular . Of note, the likely region of interactions between NT family b-turn loop II and Trks is the juxtamembrane extracellular domain, which to date has not undergone crystallographic or other detailed structural analysis (Wehrman et al., 2007) . Trk activation by small molecules may also occur via binding to pre-formed Trk dimers. Previous studies have shown that most TrkB receptors are present in a pre-formed homodimeric form before ligand binding in living cells (Shen and Maruyama, 2012) , as is TrkA (Shen and Maruyama, 2011) , and small molecules may activate dimeric receptors (Jiang and Hunter, 1999; Livnah et al., 1999) . Furthermore, there are alternative models of dimeric receptor activation by which small molecules could exert their effects, including: 1) binding to monomeric receptors inducing a conformational change leading to dimerization and activation; and 2) binding to receptor sites other than the ligand-binding domain to cause dimerization via allosteric mechanisms (for review see Longo and Massa (2013) ).
Further work on the structural changes induced in Trks by these small molecules will be needed to determine whether a common mechanism is present. Should this be the case, it might be possible to develop 'designer' small molecule ligands that preferentially activate each of the three possible pairs of Trks (A-B, A-C, B-C) and thereby offer, with potentially less off-target effects and more consistent distribution than using multiple monospecific compounds, providing a best fit for targeting various mechanisms of interest or pathological processes, depending on the populations of neurons involved. For example, TrkB and TrkC agonist antibodies have been found to improve morphological and functional outcomes in a mouse model of Charcot-Marie-Tooth peripheral neuropathy with the combination of TrkB and TrkC antibodies achieving greater effects than either alone (Sahenk et al., 2010) . Moreover, a TrkB/C activator might affect a desired population of neurons while avoiding the pain upregulation mechanisms triggered by TrkA activation. Other disease relevant neuronal populations expressing both TrkB and TrkC include those degenerating in Alzheimer's, Parkinson's and Huntington's diseases and trials with LM22B-10 in corresponding mouse models are underway.
Among various drug development strategies, a promising modern approach consists of designing multi-target-directed ligands for complex diseases with functional synergy (Guzior et al., 2015) . The ability of LM22B-10 to trigger activation of TrkB, TrkC and their numerous downstream signaling intermediates in vivo in the hippocampus and striatum and its ability to increase spine density in aged mice raise the possibility that LM22B-10 class ligands might be applied to disorders involving loss of dendritic spines and synaptic dysfunction across populations of neurons expressing TrkB and TrkC, which includes a wide range of neurological and neuropsychiatric disorders. Serafini et al., 2014; Zhang et al., 2015) .
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